The Signaling and Cell Biology Axis focuses on elucidating the fundamental mechanisms that regulate intercellular communication and intracellular processes involved in cancer formation and progression. This work covers essential biological processes such as cell division, migration, cell polarity and the associated signaling mechanisms. The aim is to understand these processes in both normal and cancerous cells in order to identify potential therapeutic targets. Using a wide range of biological models, from the nematode C. elegans and the Drosophila fly to mice and human cell lines, the teams in this axis combine experimental approaches and cutting-edge technological tools to generate transferable knowledge.
These efforts aim not only to reveal complex biological mechanisms, but also to characterize and validate innovative therapeutic targets likely to interrupt the pathways involved in cell proliferation and metastasis. By exploring mechanisms such as activation of signaling pathways, regulation of cell division, and molecular interactions influencing tumor progression, this axis contributes directly to the development of novel and promising therapeutic strategies to counter cancers resistant to current treatments.
Axis leader: Gregory Emery
Primary affiliations : Vincent Archambault, Michel Bouvier, Sébastien Carréno, Jean-Claude Labbé, Philippe Roux, Matthew Smith, Marc Therrien.
Secondary affiliations : Geneviève Deblois, Etienne Gagnon, David Knapp, Sylvie Mader, Sylvain Meloche.
Principal Investigators
-
Vincent Archambault
Cell Cycle Regulation
-
Michel Bouvier
Molecular Pharmacology
-
Sébastien Carréno
Cellular Mechanisms of Morphogenesis during Mitosis and Cell Motility
-
Gregory Emery
Vesicular Trafficking and Cell Signalling
-
Jean-Claude Labbé
Cell Division and Differentiation
-
Philippe P. Roux
Cell Signaling and Proteomics
-
Matthew Smith
Cancer Signalling and Structural Biology
-
Marc Therrien
Intracellular Signalling
Publications
-
February 19, 2026 The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.
Acevedo M, Dô F, El-Mortada F, Tanguay PL, Voisin L, Houles T, Lavoie G, Allard D, Roux PP, Stagg J, Doré S, Walsh L, Fourtounis J, Bonneil E, Meloche S, Servant MJ
Oncogene 2026-02-19 ; -
February 17, 2026 From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective N-Formyl Peptide Receptor 2 Agonist.
Shirude PS, Cheney D, Chattopadhyay AK, Seshadri B, Baligar V, Rachamreddy C, Madduri S, Anjanappa P, Viet A, Valente MN, Rossi K, Abousleiman M, Hsu MY, Everlof G, Gali V, Sun Y, Allocco J, Zhang R, St-Onge S, Lupisella J, Chen XQ, Sarodaya S, Ravindran MS, Tagore DM, Nagar J, Dudhgaonkar S, Putlur S, Héroux M, Bouvier M, Wexler RR, Dierks E, Garcia RA, Kick EK, Wurtz NR
J Med Chem 2026-02-17 ; -
January 30, 2026 A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.
Coulombe-Huntington J, Bertomeu T, Huard C, Chatr-Aryamontri A, St-Cyr DJ, Sánchez-Osuna M, Papadopoli D, Normandin K, Paydar M, McLaughlan S, St-Denis C, Zhang L, Say H, Palou R, Stark C, Breitkreutz BJ, van der Sloot AM, Manohar S, Lavoie H, Borden K, Raught B, D'Amours D, Sicheri F, Verreault A, Mader S, Meloche S, Therrien M, Thibault P, Wilhelm B, Dirks PB, Aitchison JD, Patton E, King RW, Roux PP, Sauvageau G, Hoang T, Marinier A, Harrington L, Kwok B, Archambault V, Topisirovic I, Tyers M
bioRxiv 2026-01-30 ; - See all publications